Vaping-Related Lung Injury: New CDC Recommendations for Primary Care Physicians

Nerandomilast, with a PDUFA date of Q4 2025, leads the potential breakthrough therapies, with inhaled treprostinil and admilparant advancing quickly behind.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Large US cohort study finds COVID-19 infection increases short-term risk of asthma, allergic rhinitis, and chronic rhinosinusitis, while vaccination lowers these risks.

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Your daily dose of the clinical news you may have missed.

Apnimed's first-in-class anti-apneic AD109 increases upper airway muscle tone during sleep; the company plans to file an NDA with the FDA in early 2026.